Panchkula-based Venus Remedies Ltd. is one of the top ten global fixed-dosage injectable manufacturer, has secured a significant tender from UNICEF for supplying ceftriaxone (1gm), a vital beta-lactam antibiotic. This achievement follows their recent Good Manufacturing Practices (GMP) approval from UNICEF, marking a milestone in their global healthcare contributions.
With commercial operations spanning 90+ countries across Europe, Australia, Africa, Asia-Pacific, Commonwealth States, Middle East, Latin America, and the Caribbean, Venus Remedies operates nine state-of-the-art facilities in Panchkula, Baddi, and Werne (Germany), supported by 11 international marketing offices. The company’s facilities are certified for ISO 9001, ISO 14001, ISO 18001, and OHSAS, with approvals including European-GMP, WHO-GMP, and Latin American GMP (INVIMA).
Ceftriaxone dry powder forms a crucial part of Venus Remedies’ antibiotic portfolio, addressing a wide spectrum of serious bacterial infections globally. The global ceftriaxone market, valued at USD 1.7 billion in 2021, is projected to grow at a CAGR of 2.9% through 2031, reaching over USD 2.2 billion.
In another strategic move, Venus Remedies has also secured an oncology tender from PAHO, supplying essential oncology drugs like bleomycin, carboplatin, cisplatin, cytarabine, doxorubicin, irinotecan, methotrexate, and vincristine. This initiative underscores their commitment to enhancing healthcare outcomes in Latin America.
These developments highlight Venus Remedies’ role in global healthcare supply chains, reaffirming their dedication to improving health outcomes worldwide through high-quality pharmaceuticals. Saransh Chaudhary – President, Global Critical Care, Venus Remedies, highlighted these achievements as significant milestones in expanding their international footprint and delivering life-saving medications.
India, as the largest provider of generic drugs globally, exported pharmaceuticals worth approximately US $16 billion in the fiscal year 2023-2024. Venus Remedies’ active participation in this export market underscores India’s prominence, especially in oncology care globally.
Aditi K. Chaudhary – President, International Business, Venus Remedies, emphasised that these tenders from UNICEF and PAHO validate the company’s commitment to accessible, high-quality healthcare solutions. She noted that the partnership with PAHO strengthens their position in the global oncology market and their dedication to addressing critical healthcare needs in Latin America.
With over 25 international GMP approvals and more than 800 marketing authorisations worldwide, Venus Remedies is poised to lead the pharmaceutical industry globally, leveraging its extensive international presence and commitment to innovation in healthcare.
Leave a Reply
You must be logged in to post a comment.